Importantly, even in patients with MSS BRAFV600E CRC, in whom a negligible response rate to ICB is expected, the combination of PD-1, BRAF and MEK inhibition yielded more than a threefold increase in cORR (25%, 95% CI 10.7–44.9%) relative to historical controls of combined BRAF/MEK alone (7%, 95% CI 1.5–19.1%) in patients without prior BRAFi. The gene discussed is MAP2K7; the disease is colorectal carcinoma.